Results 211 to 220 of about 366,512 (248)
Some of the next articles are maybe not open access.
Shiga Toxin: Purification, Structure, and Function
Clinical Infectious Diseases, 1991Shiga toxin is a potent toxin produced by Shigella dysenteriae type 1 strains. The toxin has three biologic activities--cytotoxicity, enterotoxicity, and neurotoxicity--and one known biochemical effect: inhibition of protein synthesis. It consists of two polypeptide chains, an A chain (molecular weight, 32,225) and a B chain (molecular weight, 7,691 ...
A, Donohue-Rolfe +2 more
openaire +2 more sources
Entry of Shiga Toxin into Cells
Zentralblatt für Bakteriologie, 1993The effect of Shiga toxin with mutations in the A fragment has been tested on cells in order to get more information about the processing of the A fragment during entry into the cytosol. A mutant with a deletion between the A1 and A2 domain in the A fragment is resistant to cleavage by trypsin and is less toxic than wild type toxin on both Vero and ...
Sandvig, Kirsten +6 more
openaire +2 more sources
Phage display and Shiga toxin neutralizers
Toxicon, 2016The current work presents an overview of the use of phage display technology for the identification and characterization of potential neutralizing agents for Shiga toxins. The last major Shiga toxin-associated disease outbreak, which took place in Germany in 2011, showed the international community that Shiga toxins remain a serious threat to public ...
Robert Alvin, Bernedo-Navarro +1 more
openaire +2 more sources
Affinity purification of Shiga-like toxin I and Shiga-like toxin II
Journal of Microbiological Methods, 1998Abstract A facile method is described for affinity purifying Shiga-like toxin I (verotoxin 1) or Shiga-like toxin II (verotoxin 2) from cell-free Escherichia coli culture supernatant solutions using immobilized synthetic analogs of the digalactoside [αGal(1,4)βGal] host cell receptor for these toxins.
George Mulvey +4 more
openaire +1 more source
Human Milk Lipids Bind Shiga Toxin
2001Hemolytic uremic syndrome, a serious complication of Shiga toxin-associated diarrhea, is rare before 6 months of age. Immunologic and nonimmunologic factors present in human milk may partially explain this observation. In prior studies, we have demonstrated that human milk contains Gb3, the receptor for the B subunit of Shiga toxin, and also contains ...
I, Herrera-Insua +5 more
openaire +2 more sources
Shiga Toxin Associated Hemolytic Uremic Syndrome
Hematology/Oncology Clinics of North America, 2015Shiga toxin associated hemolytic uremic syndrome (Stx HUS), a thrombotic microangiopathy, is the most common cause of pediatric acute kidney injury but has no direct treatment. A better understanding of disease pathogenesis may help identify new therapeutic targets. For this reason, the role of complement is being actively studied while eculizumab, the
openaire +2 more sources
Journal of natural toxins, 2001
The Stx family contains two types called Stx1 (verotoxin 1: VT1 or Shiga-like toxin: SLT1) and Stx2 (VT2, SLT2); both toxins are encoded by bacteriophages. Stx1 is identical to Shiga toxin produced by Shigella dysenteriae type I. Stx2 is heterogeneous and immunologically different from Stx1. Although many variations are found in Stx family, all Stx has
H, Nakao, T, Takeda
openaire +1 more source
The Stx family contains two types called Stx1 (verotoxin 1: VT1 or Shiga-like toxin: SLT1) and Stx2 (VT2, SLT2); both toxins are encoded by bacteriophages. Stx1 is identical to Shiga toxin produced by Shigella dysenteriae type I. Stx2 is heterogeneous and immunologically different from Stx1. Although many variations are found in Stx family, all Stx has
H, Nakao, T, Takeda
openaire +1 more source
Shiga toxin-associated hemolytic uremic syndrome
The American Journal of the Medical Sciences, 2022Tokio, Sasaki, Yuji, Suzuki
openaire +2 more sources